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Estimates of insulin resistance and postprandial measures 477Insulin resistance;
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HaplotypesMethods and results: We investigated variation within the IL18 gene and its association with
measures of obesity and the metabolic syndrome. Five IL18 tagging single nucleotide polymor-
phisms (rs1946519, rs2043055, rs549908, rs360729, rs3882891) were selected and genotyped in
the Gene-Diet Attica Investigation on childhood obesity (GENDAI) (age range 10e14 yrs); in
young European men in the second European Atherosclerosis Research offspring Study (EARSII),
an offspring study (age range 18e28 yrs) and in a group of healthy women from the Greek Ob-
ese Women study (GrOW) (age range 18e74 yrs). Six common haplotypes were observed. In
GrOW, Hap6 (Frequency-2.6%) was associated with higher insulin levels (p< 0.0001), estimates
of HOMA-Insulin Resistance (p< 0.0001) and HOMA-b-cell (p< 0.0001) compared to the common
haplotype Hap1 (Frequency-33.2%). In EARSII, rs2043055 was associated with peak and area
under the curve triglycerides (pZ 0.001 and pZ 0.002, respectively) after an oral fat toler-
ance test in ‘cases’ but not ‘controls’. None of the haplotypes were associated with measures
of body fatness in any of the studies.
Conclusion: Association of IL18 variation with insulin levels and estimates of insulin resistance
were only observed in our adult study, suggesting that the effects of IL-18 are only associated
with increasing age. Taken together with the association of IL18 variants with post-prandial
measures, this provides support for IL-18 as a metabolic factor.
ª 2010 Elsevier B.V. Open access under CC BY license.Introduction
Interleukin-18 (IL-18), a pro-inflammatory cytokine
produced by macrophages, is involved in both adaptive and
innate immune responses [1]. IL-18 stimulates interferon-g
production in T-lymphocytes and natural killer cells, both
of which play a role in atherosclerotic progression [2]. IL-18
expression is up-regulated in atherosclerotic plaques and
associated with the presence of pathological signs of plaque
instability [3]. IL-18 levels have since been confirmed as an
independent predictor of coronary events in healthy middle
aged men [4].
More recently IL-18 has been suggested to be an adipo-
genic cytokine [5], associated with excess adiposity [6].
Adipocytes from obese individuals produce higher levels of
IL-18 compared to lean individuals [7] and higher circu-
lating IL-18 levels were observed in obese individuals [8],
and those with Type 2 Diabetes (T2D) and the metabolic
syndrome [9]. Several studies have suggested that muscle is
the major source of circulating IL-18 in humans, and not
adipocytes [10,11]. Nevertheless, IL-18 levels have been
have been consistently associated with insulin resistance
measured by the homeostasis model assessment (HOMA)
[12] and studies in humans [13] and il18 / mice [14]
suggest a possible role for IL-18 in insulin sensitivity and
energy homeostasis.
Variation in IL18 has been associated with IL-18 levels and
measures of obesity in men with T2D and subjects with
advanced coronary heart disease [15] and with insulin
sensitivity in the Catanzaro Metabolic Risk (CATAMERI) study
in Italy [16]. We sought to investigate the association of IL-18
gene variants with measures of obesity and the metabolic
syndrome in different age ranges; in healthy children who
participated in the Gene e Diet Attica Investigation on
childhood obesity (GENDAI) (aged10e14 years) anda groupof
healthy women from the Greek Obese Women study (GrOW)
(aged 18e74 years). We also examined the effect of these
IL18 variants in response to an oral fat tolerance test (OFTT)
and an oral glucose tolerance test (OGTT) in youngmen (aged
18e28 years) in the second European AtherosclerosisResearch Study (EARSII), an offspring study of ‘cases’ with
a paternal history of premature coronary heart disease (CHD)
with matched ‘controls’.
Methods
Study populations
Gene e Diet Attica Investigation on childhood obesity
(GENDAI)
Subjects were recruited from public schools in the Attica
region of Greece and a total of 1138 children were
enrolled. Due to the heterogeneity in allele frequencies
between Greek and non-Greek Caucasians, only children of
Greek nationality (mean age: 11.2 0.7 years; nZ 882;
418 males and 464 females) were included in the present
study. Details of recruitment, body composition assess-
ment and biochemical analysis have been previously
described [17]. Parents or guardians and participating
children gave their informed consent prior to inclusion in
the study. The study was approved by the Institutional
Review Board of Harokopio University and the Greek
Ministry of Education.
European Atherosclerosis Research case control Study
(EARSII)
Subjects were recruited from 14 European university
student populations, men aged 18e28 years, from 11
European countries. The countries were divided into four
regions: Baltic (Estonia and Finland); United Kingdom;
Middle Europe (Belgium, Denmark, Germany, and
Switzerland); and South Europe (Greece, Italy, Portugal,
and Spain). The study comprises ‘Cases’, classified on the
basis of their father having an early myocardial infarct (MI)
(pre-55 years; nZ 407) and age-matched controls
(nZ 415). Each participant was administered a standard
OGTT (100 mg) and a standardised OFTT (1493Kcal) after
a 12-h overnight fast. Venous blood samples were drawn at
0, 30, 60, 90, and 120 min after OGTT for determination of
insulin and glucose concentrations and at 0, 2, 3, 4 and 6 h
478 M.C. Smart et al.after OFTT for triglyceride concentrations. Details of these
assays have been reported previously [18].
Greek Obese Women Study (GrOW)
A total of 379 women of Greek origin without a known
history of diabetes, cardiovascular disease or cancer were
enrolled in this study, which was approved by the Institu-
tional Review Board of Harokopio University. All partici-
pants gave their informed consent. Details of body
composition assessment and biochemical analysis have
been previously described [19]. Fasting glucose concen-
trations >126 mg/dL, cortisol treatment and lipid lowering
medication were criteria for exclusion from the analysis.
Thus, our analysis was restricted to 349 apparently healthy
women without diabetes or cardiovascular disease (CVD).
Experimental procedures
Tagging single nucleotide polymorphism identification
There are two known functional variants within the promoter
(rs187238) and 30 untranslated region (UTR) (rs5744292) of the
IL18 gene [16], however, wewanted to capture asmuch of the
variationacross the IL18geneaspossible.Therefore, a tagging
singlenucleotidepolymorphism (tSNP) set comprising variants
9731 G> T, 5848 T> C, þ4860A> C, þ8855 T>A, and
þ11015 T>G (rs1946519, rs2043055, rs549908, rs360729,
rs3882891, respectively) was selected, based on haplotypes
derived from the Innate Immunity PGA (IIPGA) Caucasian re-
sequencing data (http://innateimmunity.net). The set was
estimated tocapturemore than90%of variationwithin the21-
kilobase IL18 region, stretching from 1 kilobase upstream to
300 base pairs downstream of the gene. The set comprises
three intronic variants (rs2043055, rs360729, rs3882891),
aproximalpromoter variant (rs1946519), andone synonymous
single nucleotide polymorphism (SNP) (rs549908) within exon
4 which have been previously studied [15].
IL18 tSNP genotyping
All five tSNPs were genotyped using TaqMan technology and
probes designed by Applied Biosciences (ABI, Warrington UK).
Fluorescence was measured with the ABI Prism 7900HT
detection system analysed with the ABI TaqMan 7900HT
v3.1software. Primers and MGB probes are available upon
request.
Insulin resistance and b-cell functionalism calculation
b-cell function and insulin resistance (IR) estimates were
derived using HOMA with the following formula: HOMA-IRZ -
fasting insulin (mIU/ml) fasting glucose (mmol/l)/22.5 [20],
HOMA-
b-cell
Z fasting insulin (mIU/ml) 20/fasting glucose
(mmol/l) 3.5 [21], quantitative insulin sensitivity check
index (QUICKI)Z 1/(log(fasting insulin (mIU/ml))þ log(fast-
ing glucose (mg/dl)) [22].
Statistical methods
The majority of statistical analyses were performed using
Intercooled Stata 10.2 for Windows (StataCorp LP, USA). A c2
test comparedobservednumbersofeachgenotypewith those
expected for a population in Hardy-Weinberg equilibrium
(HWE). Data were transformed, when necessary to approxi-
mate a normal distribution. tSNPs were first analysed indi-
vidually for association with baseline and post-prandialmeasures. Linear regressions were used for association anal-
yses. Covariateswere established using a backwards stepwise
regression. Covariates for GENDAI included; height, age,
gender, BMI and mean Tanner score. Covariates for EARSII
included; BMI, smoking, age, region, and fasting levels when
analysing post-prandial data. Covariates for GrOW included;
age, estrogen use, smoking status, menopausal status and
body fat%.Pvalues less than0.01wereconsideredsignificant.
For theunivariate analyses, setting a threshold of significance
was the chosen method above Bonferroni corrections.
Linkage disequilibrium (LD) between sites was estimated
in Stata with the pairwise Lewontin’s D’ and r2 using the
pwld function (http://www-gene.cimr.cam.ac.uk/clayton/
software). Haplotype association analysis was carried out
using THESIAS [23] and PHASE version [24]. Significant haplo-
type data was adjusted for multiple comparisons using Bon-
ferroni and the false discovery rate (FDR) estimated. P values
are those given by PHASE. P values less than 0.01 were
considered significant. Analysis was limited to the six most
common haplotypes (frequency >1%) in all studies.
Results
Baseline characteristics
The baseline characteristics of the participants in the three
studies are presented in Table 1. More than a third of the
children in GENDAI were overweight with 9.5% being obese.
Subjects were classified as obese, overweight and non-
overweight according to the International Obesity Task Force
[17]. Measures of blood pressure, insulin, triglycerides,
height and insulin resistance were significantly higher
(P< 0.0001) and high density lipoprotein cholesterol signifi-
cantly lower (P< 0.0001) in the overweight and obese group
compared to their normal weight counterparts (data not
shown). The young men in EARSII were all of a normal BMI,
mean 23.10 kg/m2 95% confidence intervals (CI) 22.91, 23.29.
There were no differences in baselinemeasures between the
offspring of the ‘cases’ and ‘controls’ with the exception of
total cholesterol levels which were significantly higher in the
cases (P< 0.001). The women in GrOW were mostly over-
weight (42.1%) and obese (34.7%), but were free of diabetes
and CVD.
Allele and haplotype frequencies in GENDAI,
EARSII and GrOW
Genotypes for all five SNPs were determined in all studies
and all genotypes were in HWE. In GENDAI there were no
allele frequency differences between boys and girls or
between normal weight children and their overweight and
obese counterparts for any of the IL18 variants. Similarly, in
EARSII allele frequencies showed no ‘case’ ‘controls’
difference (data not shown). The genotypes and minor
allele frequencies (MAF) for the IL18 variants are shown in
Appendices Table 1. High LD was observed between the five
tSNPs in all three studies. D’ values were between 0.75 and
1 and r2 values between 0.14 and 1 (Fig. 1).
Haplotypes were inferred by PHASE separately in all
study groups. In total, six common haplotypes were
observed and their frequencies are shown in Table 2. The
Table 1 Baseline characteristics of the Gene-Diet Attica Investigation on childhood obesity (GENDAI), European Atherosclerosis Research case control Study (EARSII) and
Greek Obese Women study (GrOW).
GENDAI (nZ 882) EARSII (nZ 822) GrOW (nZ 349) P value
Mean 95%CI Mean 95%CI Mean 95%CI p1 p2 p3
BMI (kg/m2) 19.92 (19.70, 20.14) 23.10 (22.91, 23.29) 28.45 (27.90, 29.00) <0.001 <0.001 <0.001
Age (years) 11.2 (11.11, 11.20) 22.87 (22.68, 23.06) 46.95 (45.68, 48.23) <0.001 <0.001 <0.001
Cholesterol (mg/dl) 185.38 (183.36, 187.41) 185.38 (183.36, 187.41) 214.59 (210.09, 219.18) <0.001 <0.001 <0.001
Triglycerides (mg/dl) 60.57 (59.24, 61.94) 79.77 (77.76, 81.82) 86.71 (82.95, 90.66) 0.008 <0.001 <0.001
HDL-cholesterol (mg/dl) 51.73 (51.01, 52.46) 45.10 (44.50, 45.71) 50.68 (49.58, 51.82) <0.001 0.123 <0.001
LDL-cholesterol (mg/dl) 119.63 (118.01, 121.29) 103.96 (101.98, 105.98) 143.63 (139.98, 147.37) <0.001 <0.001 <0.001
Glucose (mg/dl) 84.97 (84.35, 85.59) 93.26 (92.71, 93.81) 94.46 (93.34, 95.60) 0.034 <0.001 <0.001
Insulin (mIU/ml) 6.83 (6.57, 7.10) 10.41 (9.95, 10.90) 7.83 (7.48, 8.20) <0.001 <0.001 <0.001
HOMA-IR 1.43 (1.38, 1.49) 2.41 (2.29, 2.53) 1.83 (1.74, 1.92) <0.001 <0.001 <0.001
HOMA-b cell 24.64 (23.57, 25.75) 127.70 (121.81, 133.86) 26.00 (24.72, 27.35) <0.001 0.163 <0.001
QUICKI 0.363 (0.361, 0.366) 0.250 (0.247, 0.252) 0.349 (0.347, 0.352) <0.001 <0.001 <0.001
Systolic Blood
Pressure (mm/Hg)
119.70 (118.70, 120.72) 116.90 (116.16, 117.63) e e <0.001 e e
Diastolic Blood
Pressure (mm/Hg)
74.02 (73.16, 74.89) 72.80 (72.09, 73.52) e e 0.035 e e
% Male 47.4 100 0 <0.001 <0.001 <0.001
% Current Smokers e 26 36 e e <0.01
Values are expressed as mean (95% confidence intervals). p1 e GENDAI vs. EARSII, p2 e GENDAI vs. GrOW, p3 e EARSII vs. GrOW.
HDL-cholesterol e High density lipoprotein cholesterol; LDL-cholesterol e Low density lipoprotein cholesterol. Insulin resistance (IR) and b-cell function were estimated using the
homeostasis model assessment (HOMA) with the following formulas: HOMA-IRZ fasting insulin (mIU/ml) x fasting glucose (mmol/l)/22.5, HOMA b-cellZ fasting insulin (mIU/ml) 20/fasting
glucose (mmol/l) 3.5, quantitative insulin sensitivity check index (QUICKI)Z 1/(log(fasting insulin (mIU/ml))þ log(fasting glucose (mg/dl)).
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Figure 1 Linkage disequilibrium between the five IL18
tagging single nucleotide polymorphisms in the Gene-Diet
Attica Investigation on childhood obesity (GENDAI), European
Atherosclerosis Research case control Study (EARSII) and the
Greek Obese Women (GrOW). Single nucleotide polymorphism
order; 9731 G> T (rs1946519), 5848 T> C (rs2043055),
þ4860 A> C (rs549908), þ8855 T>A (rs360729), þ11015 T>G
(rs3882891). Colour represents D’ - D’ .95-1; - D’.80-.94; -
D’ e .75-.79. Values represent r2.
480 M.C. Smart et al.rank order of haplotype frequencies were not the same for
the three studies and frequencies varied significantly
between the two Greek cohorts, GENDAI and GrOW (Global
PZ 0.006). There is also a significant difference in the
frequencies between EARSII and GENDAI (Global PZ 0.001)
and EARSII and GrOW (Global P< 0.0001).
IL18 univariate and haplotype associations
with baseline and post-prandial measures
We investigated the effect of IL18 variants on intermediate
phenotypes of the metabolic syndrome in each of the three
studies. The effect on post-prandial measures following anOFTT and OGTT in EARSII were also examined. tSNPs
rs549908 and rs360729 are in complete LD with functional
promoter variant rs187238. tSNPs rs1946519 and 3882891
are in complete LD with the 30 UTR functional variant
rs5744292 [16]. rs2043055 was not in LD with either of the
functional SNPs.
GENDAI
Apart from a modest association with rs2043055 on SBP and
DBP (Appendices Table 2), no associations were statistically
significant in the combined haplotype analysis with any
baseline measures in the total sample (Table 3) or when the
cohort was dichotomised by BMI (Data not shown).
EARSII
rs2043055 was significantly associated with peak and area
under the curve (AUC) triglycerides after an OFTT in the
subjects classified as ‘cases’ (PZ 0.001 for both). Homo-
zygotes of the less frequent C allele had 17.63 mg/dl
lower peak triglycerides and 0.7 less AUC compared to
common T allele homozygotes. The same trend was
observed in the ‘controls’ but did not reach statistical
significance (Table 4). There was no interaction of case:
control status with rs2043055 and no effect on post-
prandial insulin and glucose. There was no association of
rs2043055 with post-prandial measures after an OGTT
(Data not shown). No associations were observed at the
haplotypic level (Table 3).
GrOW
rs2043055 C allele homozygotes exhibited higher insulin
levels (PZ 0.054), a higher HOMA-IR estimate (PZ 0.035)
and a lower QUICKI estimate (PZ 0.048) in comparison to
carriers for the common T allele (Appendices Table 3).
However, these associations did not reach statistical
significance.
Highly significant associations were observed after
haploytpe analysis with plasma insulin levels, HOMA-IR,
HOMA-b-cell, and QUICKI estimates (Global P< 0.0001 for all
associations) (Table 3). After further analysis and Bonfer-
roni correction, it was observed that the phenotypic mean
for insulin, HOMA-IR and HOMA-b-cell was significantly higher
for Hap6 in comparison to the common haplotype, Hap1
(Bonferroni P< 0.001 for all associations). Insulin levels
were 5.56 mIU/ml higher; HOMA-IR and HOMA-b-cell estimates
were 1.34 and 20.75 higher, respectively. Furthermore,
QUICKI was significantly lower in Hap6 in comparison to
Hap1 (Bonferroni P< 0.001). The FDR for these associations
was between 0.001 and 0.003% (q-value 0.001e0.003).
Discussion
The major findings from this study are the effects of vari-
ation within IL-18 using combined haplotypes analysis, on
insulin levels and estimates of insulin resistance. Further-
more, this is the first report of the influence of a variation
within IL18 on post-prandial triglyceride levels, supporting
the idea of IL-18 playing a role in metabolic processes.
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Estimates of insulin resistance and postprandial measures 481Examining the SNPs individually, by univariate analysis in
all three studies, associations were seen only with
rs2043055. In EARSII there was a significant association of
rs2043055 with peak and AUC triglycerides after an OFTT in
the subjects classified as cases in EARSII. Homozygotes of
the less frequent C allele had significantly lower peak
triglycerides and smaller AUC compared to T allele homo-
zygotes. These results suggest carriers of the C allele clear
or absorb triglycerides faster than TT individuals and
support the idea of IL-18 playing a role in metabolic
processes. Post-prandial measures were not available in the
GrOW study and therefore the associations observed in
EARSII could not be replicated. However, there have
previous reports of rs2043055 and its potential functionality
as the variant distinguishes haplotypes associated with BMI
[15] and IL-18 levels in healthy men and coronary artery
bypass graft patients [25].
Considering the combined effect of the SNPs in haplo-
type analysis, six common haplotypes were observed,
although frequencies varied significantly between the three
studies. The allele frequencies and overall patterns of LD
were similar in these studies yet the haplotype frequency
differed, even among the two Greek studies. Haplotype
diversity can have implications for designing association
studies from genetically distinct populations and there is
evidence in EARSII of allele frequency differences across
Europe [26]. We have no explanation for this difference in
haplotype frequency but it may reflect variation in selec-
tion criteria.
The haploytpe analysis in the 2 younger groups, GENDAI
and EARSII, showed no association with intermediate
traits. However in GrOW, one haplotype, Hap6, was asso-
ciated with effects on insulin levels and estimates of
insulin resistance and sensitivity. Compared to Hap1, Hap6
that was associated with higher plasma insulin levels and
higher estimates of HOMA-IR and HOMA-b-cell in the GrOW
study. The HOMA model is used to give an estimate of
insulin sensitivity and ß-cell function from fasting plasma
insulin and glucose concentrations [20]. The associations
observed in GrOW suggest that those women who carried
the Hap6 haplotype showed some insulin resistance, since
as they had higher plasma insulin, but their glucose levels
do not differ significantly from the other haplotypes. This is
further supported by the QUICKI estimate of insulin sensi-
tivity which is significantly lower in those with Hap6.
QUICKI estimates have been shown to be lower in those
who are overweight and diabetic when compared to non-
obese and non-diabetic individulas [22]. It also appears
that Hap6 carriers are yet to develop becell failure as their
HOMA-b-cell estimate is higher than those with Hap1.
Hap6 is relatively uncommon in GrOW (Frequency 2.6%).
For this reason we repeated the haplotype analyses using
the THESIAS program and utilised a bootstrap approach to
take the uncertainty of inferring haplotypes into account,
although studies have suggested that correcting or adjust-
ing for uncertainty has little effect with inferred haplotypes
[27]. All associations remained significant when repeated. A
recent study of non-diabetic Caucasians reported the
association of promoter variant, þ183A> G (rs5744292),
which is in complete LD with rs1946519 and rs3882891, with
increased levels of serum IL-18, increased risk of metabolic
syndrome and impaired insulin sensitivity [16]. Insulin
Table 3 Haplotypic mean for baseline and post-prandial measures in the Gene-Diet Attica Investigation on childhood obesity (GENDAI), European Atherosclerosis Research
case control Study (EARSII) and Greek Obese Women (GrOW).
n BMI (kg/m2) Triglycerides (mg/dl) Insulin (mIU/ml) Glucose (mg/dl) HOMA-IR HOMA b-cell QUICKI
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
GENDAI
Hap1 (12111) 669 20.13 0.13 65.24 0.86 7.96 0.19 85.50 0.37 1.73 0.05 29.57 0.73 0.37 0.00
Hap2 (21222) 401 20.10 0.17 63.91 1.12 7.92 0.25 85.18 0.47 1.69 0.06 29.94 0.95 0.37 0.00
Hap3 (11111) 358 20.30 0.18 63.19 1.17 8.11 0.25 85.52 0.50 1.73 0.07 30.39 0.99 0.37 0.00
Hap4 (21112) 251 20.56 0.21 63.40 1.39 8.02 0.30 86.22 0.59 1.73 0.08 29.99 1.18 0.36 0.00
Hap5 (22111) 29 21.23 0.63 60.60 4.08 8.18 0.88 85.87 1.73 1.74 0.23 31.11 3.43 0.37 0.01
Hap6 (12222) 27 19.53 0.65 62.10 4.22 7.48 0.91 84.08 1.79 1.58 0.24 28.52 3.55 0.37 0.01
Global P value 0.191 0.605 0.983 0.759 0.982 0.981 0.821
EARSII
Hap1 (12111) 442 22.51 0.4 71.75 3.94 12.93 0.64 93.53 1.08 2.96 0.16 145.73 14.57 0.26 0.06
Hap2 (21222) 363 22.32 0.4 69.35 4.34 12.13 0.58 93.21 1.06 2.81 0.14 132.13 10.57 0.24 0.03
Hap3 (11111) 325 22.00 0.4 70.38 4.48 13.25 0.69 95.56 1.06 3.16 0.17 151.01 15.93 0.28 0.04
Hap4 (21112) 169 22.26 0.5 59.04 5.51 12.00 0.97 93.22 1.47 2.77 0.24 142.95 21.55 0.27 0.07
Hap5 (22111) 24 22.60 1.1 109.52 9.84 15.53 2.87 99.03 3.02 3.88 0.71 168.66 72.80 0.26 0.46
Hap6 (12222) 35 22.55 1.1 55.94 15.81 12.51 2.66 92.93 3.89 2.89 0.62 161.77 99.15 0.29 0.29
Global P value 0.84 0.458 0.495 0.202 0.247 0.792 0.69
GrOW
Hap1 (12111) 232 29.42 0.67 95.24 5.60 7.82 0.53 95.25 1.24 1.87 0.13 26.01 2.04 0.35 0.00
Hap2 (21222) 136 29.65 0.71 94.01 5.93 7.44 0.56 94.89 1.32 1.77 0.14 24.71 2.16 0.36 0.00
Hap3 (11111) 171 28.63 0.72 97.41 5.97 7.95 0.56 93.18 1.32 1.85 0.14 27.36 2.17 0.35 0.00
Hap4 (21112) 124 28.81 0.77 97.16 6.36 7.43 0.60 93.78 1.41 1.74 0.15 25.14 2.32 0.36 0.00
Hap5 (22111) 12 27.98 1.71 105.60 14.21 8.75 1.33 95.73 3.15 2.09 0.33 29.53 5.17 0.35 0.01
Hap6 (12222) 18 29.34 1.41 87.68 11.67 13.38 1.10 95.64 2.59 3.21 0.27 46.76 4.25 0.33 0.01
Global P value 0.533 0.892 <0.001 0.436 <0.001 <0.001 0.001
Bonferroni P value <0.001 <0.001 <0.001 <0.001
Data are presented as mean (standard error).
Single nucleotide polymorphism order; 9731 G> T (rs1946519), 5848 T> C (rs2043055), þ4860 A> C (rs549908), þ8855 T>A (rs360729), þ11015 T>G (rs3882891).
GENDAI; all blood measures are adjusted for height, age, gender and BMI and anthropometric measures are adjusted for height, age, gender and mean Tanner score; Tanner stage
(an estimate of pubertal status) was combined into one variable from the two Tanner measures to produce a mean Tanner score.
EARSII; all blood measures are adjusted for age, region, smoking status and BMI and anthropometric measures are adjusted for age, region and smoking status.
GrOW; all blood measures are adjusted for age, estrogen use, smoking status, menopausal status and body fat % and anthropometric measures are adjusted for age, estrogen use, smoking
status and menopausal status.
Insulin resistance (IR) and b-cell function were estimated using the homeostasis model assessment (HOMA) with the following formulas: HOMA-IRZ fasting insulin (mIU/ml) fasting glucose
(mmol/l)/22.5, HOMA-b-cellZ fasting insulin (mIU/ml) 20/fasting glucose (mmol/l) 3.5, quantitative insulin sensitivity check index (QUICKI)Z 1/(log(fasting insulin (mIU/ml))þ log(-
fasting glucose (mg/dl)).
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Table 4 A. Effect of IL18 -5848 variant on peak triglyc-
erides after an oral fat tolerance test by case-control status
in the European Atherosclerosis Research case control Study
(EARSII). B. Effect of IL18 -5848 variant on the area under
the curve of triglycerides after an oral fat tolerance test by
case-control status in EARSII.
IL18 -5848
Genotype
Controls Cases
n Mean (SE) n Mean (SE)
A Peak Triglycerides (mg/dl)
TT 149 95.57 (3.63) 122 100.24 (4.19)
TC 161 95.68 (3.54) 160 93.13 (3.35)
CC 45 85.58 (5.99) 48 74.79 (4.97)
pZ 0.294 pZ 0.001
B Area under the curve for Triglycerides
TT 160 3.669 (0.157) 132 3.956 (0.167)
TC 167 3.516 (0.146) 170 3.606 (0.139)
CC 52 3.291 (0.272) 49 2.993 (0.232)
pZ 0.222 pZ 0.002
Data are presented as mean (standard error) by IL18 -5848 T> C
genotype (rs2043055). Adjusted for age, region, smoking status,
BMI and fasting plasma triglyceride levels.
Estimates of insulin resistance and postprandial measures 483sensitivity was significantly higher in subjects carrying the
G allele and circulating IL-18 levels significantly lower. The
C allele of the 137 G> C polymorphism (rs187238), which
is in complete LD with rs549908 and rs360729, in the
promoter region has also been associated with lower tran-
scriptional activity [28]. The effect of variants on IL-18
levels and their association with insulin levels and sensi-
tivity suggests that insulin sensitivity and metabolic
syndrome may have a genetic basis [16].
IL18 haplotypic effects on BMI have been reported in T2D
and in subjects undergoing coronary artery bypass surgery
[15]. However, in a healthy cohort of 3012 middle aged men
single SNP and haplotype analysis with five IL18 tSNPs
showed no effect on BMI. There is an apparent absence of
effect of IL18 variation on BMI within all three of our
studies. Bodyweight differences were only seen in the
mouse il-18 knock-out model in comparison to their wild-
type littermates after sixmonths of age and older [13]. Thus
the effect IL18 may only become apparent as subjects age
and therefore the lack of effect in GENDAI and EARSII is not
unexpected. It would appear the lack of association in
GrOWmay be due the study population, as those with a BMI
over 30 are over represented, and power was limited.
Furthermore, the participants in GrOW, although many
were overweight, they were healthy. This is unlike the
diseased cohorts which have reported the effect on BMI
[15]. It is possible that the effects of IL-18 are exacerbated
by disease.
Data presented on the il18 knockout mouse suggested
that il-18 was a satiety factor and was likely to be exerting
its effect on the hypothalamus. Therefore, it seems
possible that the IL-18 effect on BMI and metabolic
syndrome may result through two distinct pathways. With
a potential causal role in atherogenesis as well as T2D, IL-18
may be implicated in a number of complex diseases and
their risk prediction. Tiret et al. [29] highlighted the role ofIL18 in cardiovascular disease, demonstrating that IL18
haplotypes were associated with variation in IL-18 serum
levels and cardiovascular mortality. These associations
have been confirmed in a number of cohorts [15,25].
Markers of inflammation are significantly higher in those
who are overweight in comparison to those of a normal
weight and the mechanism whereby genetic variation of
IL18 is involved in the development of diabetes and meta-
bolic syndrome is likely to be affected by inflammation and
activated innate immunity [30,31].
In conclusion, the association of genetic variation within
IL18 on insulin levels and estimates of insulin resistance
were only observed in our older GrOW study, suggesting
that the effects of IL-18 appear to be more prominent as we
age. Furthermore, the association of IL18 variants with
post-prandial measures provide support for IL-18 as
a metabolic factor.
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